The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)

The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)
TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Background
  • Scope and Methodology
  • Size and Growth of the Market
  • Key Issues and Trends Affecting Market
  • Leading Competitors
CHAPTER TWO: INTRODUCTION
  • Overview
  • Structural Organization of the Neurological System
    • Central Nervous System
    • The Brain
  • Aging and Alzheimer’s Disease
  • Stages of Alzheimer’s Disease
  • Risk Factors
  • Life Expectancy and the Growing Incidence of Alzheimer’s Disease
  • World Demographics
  • Prevalence, Incidence and Mortality
  • Insurance for the Elderly in the United States
  • Generic Competition
    • Teva/Mutual Pharmaceutical/United Research Laboratories and Eisai
    • Dr. Reddy’s and Novartis
    • Ranbaxy and Ortho-McNeil Neurologics
CHAPTER THREE: ALZHEIMER’S DISEASE PRODUCT ANALYSIS
  • Overview of Products
  • Aricept
  • Namenda/Exiba/Axura
  • Exelon
  • Razadyne
  • Other Products
CHAPTER FOUR: RESEARCH AND DEVELOPMENT
  • Overview
  • Phase III
    • AAB-001
    • Aricept SR
    • Exelon Transdermal Patch (ONO 2540)
    • Flurizan
    • LY450139
    • Memryte
    • Namenda Once-Daily
    • Rosiglitazone XR
    • Xaliproden
    Phase II
    • Dimebon
    • AC-1202
    • Ispronicline
    • MEM-3454
    • MEM-1003
    • AN-1792
    • ABT-089
    • ACC-001 and QS-21
    • AL-108
    • CX717
    • ELND-005
    • Huperzine A
    • Immune globulin, intravenous
    • LY2062430
    • Lecozotan SR
    • MK-0249
    • MK-0952
    • Neramenxane
    • NIC5-15
    • PRX-03140
    • Rasagiline mesylate
    • SAM-531
    • SGS742
    • T 817 MA
    • TTP 488
    Phase I
    • 933776
    • Aricept Transdermal Patch
    • AV 965
    • AVE 8112
    • Bapineuzumab
    • CAD-106
    • CERE-110
    • CTS-21166
    • EVP 6124
    • GSI 953
    • Lecozotan SR
    • MEM-1414
    • NGX267
    • Oxigon
    • Paz-417
    • PF-4360365
    • PF-30804014
    • R1450
    • R4996/MEM 63908
    • SSR 180711
    • V 950
    Preclinical Development
    • TTP 4000
    • AAB-002
    • Alzhemed
    • BACE Inhibitors (TTP 854)
    • CX1739
    • E2012
    • Gamma-secretase inhibitor
    • GSI-136
    • MEM-1917
    • MPI-442690
    • PBT2/PBT3/PBT4
    • SAR 110894
CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS
  • Market Overview
  • Market Analysis by Product Type
  • Market Analysis by Country
  • Competitive Analysis
  • Leading Products
CHAPTER SIX: LEADING MANUFACTURERS
  • Overview
  • Eisai Co., Ltd.
  • Forest Laboratories
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merz Pharma GmbH
  • Novartis AG
  • Pfizer, Inc.
APPENDIX: LIST OF MAJOR COMPANIES LIST OF EXHIBITS CHAPTER ONE: EXECUTIVE SUMMARY
  • Figure 1-1: Alzheimer’s Disease Market Analysis: 2005-2012
CHAPTER TWO: INTRODUCTION
  • Table 2-1: Alzheimer’s Disease Stages 1-7 and Descriptions
  • Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2006
  • Figure 2-1: Average Life Expectancy in Years by Country 1980, 2004 and 2006
  • Table 2-3: World Population by Selected Geographical Region, 2007 - 2050
  • Figure 2-2: World Population by Selected Geographical Region, 2007-2050
  • Table 2-4: Estimated World Population by Age and Geographical Region, 2007
  • Figure 2-3: Estimated World Population by Age and Geographical Region, 2007
  • Table 2-5: Percent Population Over 65 by Year and Region
  • Figure 2-4: Estimated World Population by Age, 2007 and 2050
  • Table 2-6: Estimated Prevalence, Incidence and Mortality for Alzheimer’s Disease* by Region/Country, 2007
  • Figure 2-5: Estimated World Prevalence and Incidence of Alzheimer’s Diseases by Region, 2007
  • Figure 2-6: World Prevalence of Alzheimer’s Disease Compared to Rest of Population Over Age 65, 2007
  • Table 2-7: Health Insurance Trends in the United States, Estimated 2007 (millions)
CHAPTER THREE: ALZHEIMER’S DISEASE PRODUCT ANALYSIS
  • Table 3-1: Comparison of Marketed Alzheimer’s Disease Treatments
  • Figure 3-1: Alzheimer Product Sales Analysis, 2005-2007
  • Figure 3-2: Aricept Sales Analysis, 2005-2007
  • Figure 3-3: Namenda/Exiba/Axura Sales Analysis, 2005-2007
  • Figure 3-4: Exelon Sales Analysis, 2005-2007
  • Figure 3-5: Razadyne Sales Analysis, 2005-2007
CHAPTER FOUR: RESEARCH AND DEVELOPMENT
  • Figure 4-1: Alzheimer’s Disease Treatments in Development, 2005, 2006, and 2007
  • Table 4-1: Alzheimer’s Disease Therapies in Development
CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS
  • Table 5-1: Alzheimer’s Disease Market Analysis, 2005-2007
  • Table 5-2: Forecasted Alzheimer’s Disease Market Analysis: 2008-2012
  • Figure 5-1: Alzheimer’s Disease Market Analysis: 2005-2012
  • Table 5-3: Alzheimer’s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
  • Figure 5-2: Alzheimer’s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
  • Figure 5-3: Alzheimer’s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005 Figure 5-4: Alzheimer’s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2007
  • Table 5-4: Alzheimer’s Disease Market Analysis by Region/Country, 2007
  • Figure 5-5: Alzheimer’s Disease Market Analysis by Region/Country, 2007
  • Table 5-5: Alzheimer’s Disease Market Estimated Revenues and Market Share of Leading Suppliers 2007
  • Figure 5-6: Alzheimer’s Disease Market Estimated Market Share by Leading Suppliers 2007
  • Table 5-6: Alzheimer’s Disease Market Estimated Sales of Top Products 2007
  • Figure 5-7 : Alzheimer’s Disease Market Estimated Market Share of Top Products, 2007
CHAPTER SIX: LEADING MANUFACTURERS
  • Figure 6-1: Eisai’s Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-2: Forest’s Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-3: Lundbeck’s Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-4: Johnson & Johnson’s Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-5: Merz Pharma’s Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-6: Novartis’ Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-7: Pfizer’s Net Revenues and R&D Expenses for 2006 and 2007